The present technology is directed generally to treatment of congestive heart failure with electrical stimulation, and associated systems and methods.
Congestive heart failure (CHF) is a chronic condition characterized by a reduction in contraction strength (e.g., contractility) of one or both of the main pumping chambers of the heart—the left and right ventricles. Reduced contractility of the ventricles reduces the volume of blood ejected by each ventricle per heart beat (e.g., stroke volume). When this occurs, the heart cannot pump blood with normal efficiency, and blood and other fluids begin to build up within the cardiovascular system and other parts of the body, such as the lungs, liver, abdomen, and lower extremities. In some cases of CHF, the myocardium (e.g., heart muscle tissue) becomes so weakened that the ventricles stretch or dilate, thereby damaging the Purkinje fibers located in the walls of the ventricles. The Purkinje fibers are responsible for carrying the contraction impulse to the myocardium of the ventricles, and thus damage to the Purkinje fibers by the dilated ventricles compromises the electrical conduction system of the heart and reduces the synchronization of contractility, further compromising the ejection fraction. Accordingly, there is a need for systems and methods for treating congestive heart failure.
The present technology is directed generally to systems for treating congestive heart failure (CHF), and in particular, to systems for treating CHF by improving contraction strength of the left and/or right ventricles via electrical stimulation. In one embodiment, the present technology includes a treatment system having an implantable signal generator and a signal delivery element configured to apply an electrical signal to a parasympathetic nerve innervating a portion of a patient's heart. The system includes one or more real-time feedback mechanisms for evaluating the efficacy of the applied signal and automatically adjusting the applied signal based on the efficacy. For example, in some embodiments the treatment system can automatically determine an ejection fraction of the patient's heart and adjust one or more parameters of the applied electrical signal based on the ejection fraction.
Definitions of selected terms are provided under heading 1.0 (“Definitions”). General aspects of the anatomical and physiological environment in which the disclosed technology operates are described below under heading 2.0 (“Introduction”) with reference to
As used herein, “vagus nerve” refers to any of the following: portions of the left vagus nerve, the right vagus nerve, and/or the cervical vagus nerve, branches of the vagus nerve such as the superior cardiac nerve, superior cardiac branch, and inferior cardiac branch, and the vagus trunk. Similarly, stimulation of the vagus nerve is described herein by way of illustration and not limitation, and it is to be understood that in some embodiments of the present technology, other autonomic and/or parasympathetic nerves and/or parasympathetic tissue are stimulated, including sites where the vagus nerve innervates a target organ, vagal ganglia, nerves in the epicardial fat pads, a carotid artery, a jugular vein (e.g., an internal jugular vein), a carotid sinus, a coronary sinus, a vena cava vein, a pulmonary vein, and/or a right ventricle, for treatment of heart conditions or other conditions.
As used herein, “high frequency” or “HF” refers to a frequency of from about 1 kHz to about 100 kHz, or from about 1.2 kHz to about 100 kHz, or from about 1.5 kHz to about 100 kHz, or from about 2 kHz to about 50 kHz, or from about 3 kHz to about 20 kHz, or from about 3 kHz to about 15 kHz, or from about 5 kHz to about 15 kHz, or from about 3 kHz to about 10 kHz, or 1 kHz, 2 kHz, 3 kHz, 4 kHz, 5 kHz, 8 kHz, 9 kHz, 10 kHz, 11 kHz, 12 kHz, 15 kHz, 20 kHz, 50 kHz, or 100 kHz. As used herein, the term “about” refers to values within +/−10% of the stated value. Moreover, as used herein, “low frequency” or “LF” refers to a frequency less than about 1 kHz.
As used herein, “real-time” refers to within 10 seconds or less, within 5 seconds or less, within 3 seconds or less, within 2 seconds or less, within 1 second or less, within 0.5 seconds or less, within 0.25 seconds or less, and within 0.1 seconds or less.
The signal generator 102 can transmit signals (e.g., electrical signals or therapy signals) to the signal delivery element 104 that up-regulate (e.g., stimulate or excite) and/or down-regulate (e.g., block or suppress) target nerves (e.g., local vagal nerves). As used herein, and unless otherwise noted, to “modulate,” “stimulate,” or provide “modulation” or “stimulation” to the target nerves refers generally to having either type of the foregoing effects on the target nerves. The signal generator 102 can include a machine-readable (e.g., computer-readable) medium containing instructions for generating and transmitting suitable therapy signals. The signal generator 102 and/or other elements of the treatment system 100 can include one or more processors 110, memories 112 and/or input/output devices. Accordingly, the process of providing electrical signals, detecting physiological parameters of the patient, determining ejection fraction, adjusting the modulation signal, and/or executing other associated functions can be performed by computer-executable instructions contained by computer-readable media located at the signal generator 102 and/or other system components. The signal generator 102 can include multiple portions, elements, and/or subsystems (e.g., for directing signals in accordance with multiple signal delivery parameters) housed in a single housing, as shown in
The signal delivery system 101 can include one or more sensing elements 140 for detecting one or more physiological parameters of the patient before, during, and/or after the application of electrical therapy signals. In some embodiments, one or more of the sensing elements 140 can be carried by the signal generator 102, the signal delivery element 104, and/or other implanted components of the system 101. In other embodiments, the sensing element(s) 140 can be an extracorporeal or implantable device separate from the signal generator 102 and/or signal delivery element 104. Representative sensing elements 140 include one or more of: an electrocardiogram (“ECG”) unit, an impedance cardiography unit, a subcutaneous sensor, a ventricular sensor, an activity sensor (e.g., an accelerometer), a ventricular intracardiac sensor, an atrial intracardiac sensor, a temperature sensor, a flow rate sensor, a chemical sensor, a biosensor, an electrochemical sensor, a hemodynamic sensor, an optical sensor and/or other suitable sensing devices. Physiological parameters detected by the sensing element(s) 140 include heart rate, blood pressure, blood flow rate, activity level, ECG readings, impedance cardiography readings, ventricular and/or atrial pressure, and/or any correlates and/or derivatives of the foregoing parameters (e.g., raw data values, including voltages and/or other directly measured values).
In a representative embodiment, the signal delivery system 101 is configured to operate in either a “calibration mode” or an “active mode.” In the calibration mode, the signal delivery system 101 is configured to apply a low frequency electrical signal (also referred to herein as the “LF calibration signal”) via the signal delivery element 104 at the treatment site to determine a representative (e.g., maximum) signal amplitude that can be applied during subsequent treatment. In one embodiment, for example, the maximum signal amplitude is determined during the calibration mode to be the lower of: (1) the amplitude at which direct, immediate changes are observed to the heart rate, myocardial activation, or chamber sequencing, and (2) the amplitude which creates sensations which are perceived by the patient. In a particular embodiment, the signal delivery system 101 is also configured to apply a high frequency electrical signal (referred to herein as the “HF calibration signal”) when in the calibration mode to validate the maximum signal amplitude identified by the LF calibration signal. In the active mode, the signal delivery system 101 is configured to apply a high frequency electrical signal (also referred to herein as the “HF treatment signal” or “HF therapy signal”) at the treatment site to modulate the parasympathetic nerves proximate the treatment site. Parameters of the electrical signals applied by the signal delivery system 101 during calibration mode and/or active mode can be (1) automatically adjusted in response to a feedback mechanism and/or in accordance with a preset program (described in greater detail with reference to
In some embodiments, the signal generator 102 can obtain power to generate the therapy signals from an external power source 114. The external power source 114 can transmit power to the implanted signal generator 102 using electromagnetic induction (e.g., RF signals). For example, the external power source 114 can include an external coil 116 that communicates with a corresponding internal coil (not shown) within the implantable signal generator 102. The external power source 114 can be portable for ease of use.
In another embodiment, the signal generator 102 can obtain the power to generate therapy signals from an internal power source, in addition to or in lieu of the external power source 114. For example, the implanted signal generator 102 can include a non-rechargeable battery or a rechargeable battery to provide such power. When the internal power source includes a rechargeable battery, the external power source 114 can be used to recharge the battery. The external power source 114 can in turn be recharged from a suitable power source (e.g., conventional wall power).
During at least some procedures, an external programmer 120 (e.g., a trial modulator) can be coupled to the signal delivery element 104 during an initial procedure, prior to implanting the signal generator 102. For example, a practitioner (e.g., a physician and/or a company representative) can use the external programmer 120 in calibration mode to vary the signal parameters provided to the signal delivery element 104 in real-time, and select optimal or particularly efficacious signal parameters and/or signal delivery element 104 placement, as discussed in greater detail below with reference to
After a trial period with the external programmer 120, the practitioner can implant the implantable signal generator 102 within the patient P for longer term treatment. The signal delivery parameters provided by the signal generator 102 can still be updated after the signal generator 102 is implanted, via a wireless physician's programmer 124 (e.g., a physician's remote).
As shown in
In a particular embodiment, the signal delivery system 101 (
Once the maximum treatment signal amplitude has been determined, the system 101 (
Application of the HF treatment signal at the treatment site (e.g., at or proximate an epicardial fat pad) is expected to modulate one or more vagal nerves at or proximate to the treatment site, thereby improving parasympathetic tone and cardiac contractility. One way to assess contractility and/or the efficacy of the treatment is by measuring ejection fraction, or the percentage of blood pumped out of the heart during each beat. An increase in ejection fraction indicates improved contractility and, likewise, a decrease in ejection fraction indicates reduced contractility. Under resting conditions, healthy adults have an average ejection fraction between 50% and 75%. Below 50%, the patient may experience a variety of symptoms, including shortness of breath, inability to exercise, swelling of the feet and lower legs, fatigue, weakness, and rapid or irregular heartbeat. Below 30%, the patient's quality of life is minimal and death may be imminent.
When the signal delivery system 101 (
In block 514, the processor 110 (
As indicated by block 530, if the EF measurement is less than the target EF threshold, the processor 110 (
As indicated by block 520, if the EF measurement is greater than or equal to the target EF threshold, the processor 110 (
It will be appreciated that in any of the above embodiments, the signal delivery system 101 (
Embodiments of the presently disclosed technology are described in the following examples. A method for treating congestive heart failure in a patient in accordance with one example includes applying an electrical signal to the patient via a treatment system that includes a signal delivery element in electrical communication with the patient's vagus nerve at a portion of the vagus nerve located at or proximate to the anterior interventricular junction of the patient's heart, with the electrical signal having a frequency of from about 1 kHz to about 100 kHz. The method further includes automatically detecting at least one physiological parameter of the patient, automatically determining at least one of an ejection fraction of the patient's heart and a correlate of the ejection fraction based on the detected parameter, and automatically adjusting the applied signal based on the determined ejection fraction. In some embodiments of the method, automatically adjusting the applied signal includes stopping the application of the applied signal in response to detecting an ejection fraction greater than or equal to a target ejection fraction threshold. In these and other embodiments, automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction less than a target ejection fraction threshold and/or automatically adjusting the applied signal includes decreasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction greater than or equal to a target ejection fraction threshold. In some embodiments, automatically detecting a physiological parameter includes automatically detecting the patient's heart rate, and automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to the increase in the patient's heart rate. Further, in at least some embodiments of the method, applying the electrical signal occurs at a first time and automatically adjusting the applied signal includes applying the electrical signal at a second time in response to detecting an ejection fraction less than the target ejection fraction threshold. In a particular embodiment, applying the electrical signal includes applying the signal to the patient via a lead positioned at or proximate to the atrial-ventricular fat pads of the patient's heart. In certain embodiments of the method, applying the electrical signal includes applying the signal with a pulse width less than or equal to 1/(2×the frequency of the signal). In further embodiments, the treatment system includes an implantable treatment system. In yet further embodiments, the at least one detected physiological parameter includes at least one of the patient's heart rate, the patient's blood pressure, and the patient's blood flow rate.
A method for treating congestive heart failure in a patient in accordance with another representative example includes applying an electrical signal having a frequency of from about 1 kHz to about 100 kHz to an epicardial fat pad of the patient's heart, automatically monitoring an ejection fraction of the patient, automatically comparing the monitored ejection fraction value to a predetermined threshold, and based on the comparison, automatically adjusting the applied signal. In some embodiments of the method, automatically adjusting the applied signal includes stopping the application of the applied signal in response to detecting an ejection fraction greater than or equal to a target ejection fraction threshold. In these and other embodiments, automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction less than a target ejection fraction threshold and/or automatically adjusting the applied signal includes decreasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction greater than or equal to a target ejection fraction threshold. In a particular embodiment of the method, applying the electrical signal occurs at a first time, and wherein automatically adjusting the applied signal includes applying the electrical signal at a second time in response to detecting an ejection fraction less than the target ejection fraction threshold.
Still a further representative example of a system for treating congestive heart failure in a patient in accordance with the present technology includes an electrical signal generator having a computer readable storage medium, and an implantable signal delivery element coupled to the signal generator. The signal generator can be configured to be positioned proximate an epicardial fat pad of the patient and apply an electrical signal having a frequency of from about 1 kHz to about 100 kHz to neural tissue proximate and/or within the epicardial fat pad. In some embodiments of the system, the computer-readable storage medium has instructions that, when executed, determine an ejection fraction of the patient's heart in real-time and adjust the signal applied by the signal delivery element in response to the determined ejection fraction. In a particular embodiment, the system further comprises a sensor in communication with the computer-readable storage medium. In at least some of such embodiments, the sensor is configured to detect a physiological parameter of the patient, and the instructions, when executed, calculate the ejection fraction based on the physiological parameter. In a certain embodiment of the system, the signal generator is an implantable signal generator. In further embodiments of the system, the instructions, when executed, and in response to a determined ejection fraction greater than or equal to a predetermined target threshold, cease to apply the electrical signal. In these and other embodiments, the instructions, when executed, and in response to a determined ejection fraction less than or equal to a predetermined target threshold, start application of the electrical signal and/or in response to a determined ejection fraction less than or equal to a predetermined target threshold, increase at least one of an amplitude or a pulse width of the electrical signal. In a representative embodiment of the system, the signal delivery element is configured to be positioned within a coronary blood vessel of the patient.
From the foregoing, it will be appreciated that specific embodiments of the disclosed technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. For example, in some embodiments the system 101 (
Certain aspects of the technology described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, in some embodiments the signal generator 102 (
To the extent any materials incorporated herein by reference conflict with the present disclosure, the present disclosure controls.
The present application is a division of U.S. patent Application Ser. No. 15/414,561 filed Jan. 24, 2017, which claims priority to U.S. Provisional Application No. 62/286,892, filed Jan. 25, 2016, and is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1597061 | Cultra | Aug 1926 | A |
3195540 | Waller | Jul 1965 | A |
3724467 | Avery et al. | Apr 1973 | A |
3727616 | Lenzkes | Apr 1973 | A |
3817254 | Maurer | Jun 1974 | A |
3822708 | Zilber | Jul 1974 | A |
3893463 | Williams | Jul 1975 | A |
4014347 | Halleck et al. | Mar 1977 | A |
4023574 | Nemec | May 1977 | A |
4055190 | Tany et al. | Oct 1977 | A |
4148321 | Wyss et al. | Apr 1979 | A |
4379462 | Borkan et al. | Apr 1983 | A |
4414986 | Dickhudt et al. | Nov 1983 | A |
4535777 | Castel | Aug 1985 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4608985 | Crish et al. | Sep 1986 | A |
4612934 | Borkan et al. | Sep 1986 | A |
4649935 | Charmillot et al. | Mar 1987 | A |
4735204 | Sussman et al. | Apr 1988 | A |
4764132 | Stutz, Jr. | Aug 1988 | A |
4793353 | Borkan et al. | Dec 1988 | A |
4841973 | Stecker | Jun 1989 | A |
RE33420 | Sussman et al. | Nov 1990 | E |
5002053 | Garcia-Rill | Mar 1991 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5354320 | Schaldach et al. | Oct 1994 | A |
5514175 | Kim et al. | May 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5562717 | Tippey | Oct 1996 | A |
5643330 | Holsheimer et al. | Jul 1997 | A |
5716377 | Rise et al. | Feb 1998 | A |
5755758 | Wolozko | May 1998 | A |
5776170 | MacDonald et al. | Jul 1998 | A |
5830151 | Hadzic et al. | Nov 1998 | A |
5853373 | Griffith et al. | Dec 1998 | A |
5893883 | Torgerson et al. | Apr 1999 | A |
5938690 | Law | Aug 1999 | A |
5983141 | Sluijter et al. | Nov 1999 | A |
5995872 | Bourgeois | Nov 1999 | A |
6002964 | Feler et al. | Dec 1999 | A |
6014588 | Fitz | Jan 2000 | A |
6027456 | Feler et al. | Feb 2000 | A |
6049701 | Sparksman | Apr 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6176242 | Rise | Jan 2001 | B1 |
6233488 | Hess | May 2001 | B1 |
6238423 | Bardy | May 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6319241 | King et al. | Nov 2001 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6356786 | Rezai et al. | Mar 2002 | B1 |
6366814 | Boveja | Apr 2002 | B1 |
6393325 | Mann et al. | May 2002 | B1 |
6397108 | Camps et al. | May 2002 | B1 |
6405079 | Ansarinia | Jun 2002 | B1 |
6421566 | Holsheimer | Jul 2002 | B1 |
6440090 | Schallhorn | Aug 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6505078 | King et al. | Jan 2003 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6526318 | Ansarinia | Feb 2003 | B1 |
6571127 | Ben-Haim et al. | May 2003 | B1 |
6584358 | Carter et al. | Jun 2003 | B2 |
6587724 | Mann | Jul 2003 | B2 |
6609030 | Rezai et al. | Aug 2003 | B1 |
6622048 | Mann et al. | Sep 2003 | B1 |
6659968 | McClure | Dec 2003 | B1 |
6662051 | Eraker et al. | Dec 2003 | B1 |
6714822 | King et al. | Mar 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6856315 | Eberlein | Feb 2005 | B2 |
6871090 | He et al. | Mar 2005 | B1 |
6871099 | Whitehurst et al. | Mar 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6907293 | Grill et al. | Jun 2005 | B2 |
6907295 | Gross et al. | Jun 2005 | B2 |
6923784 | Stein | Aug 2005 | B2 |
6928230 | Squibbs | Aug 2005 | B2 |
6928320 | King | Aug 2005 | B2 |
6950707 | Whitehurst | Sep 2005 | B2 |
6968237 | Doan et al. | Nov 2005 | B2 |
6990376 | Tanagho et al. | Jan 2006 | B2 |
7024246 | Acosta et al. | Apr 2006 | B2 |
7047079 | Erickson | May 2006 | B2 |
7054686 | MacDonald | May 2006 | B2 |
7082333 | Bauhahn et al. | Jul 2006 | B1 |
7117034 | Kronberg | Oct 2006 | B2 |
7146224 | King | Dec 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7162304 | Bradley | Jan 2007 | B1 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7174215 | Bradley | Feb 2007 | B2 |
7177702 | Wallace et al. | Feb 2007 | B2 |
7180760 | Varrichio et al. | Feb 2007 | B2 |
7206640 | Overstreet | Apr 2007 | B1 |
7212865 | Cory | May 2007 | B2 |
7225035 | Brabec et al. | May 2007 | B2 |
7236822 | Dobak, III | Jun 2007 | B2 |
7236830 | Gliner | Jun 2007 | B2 |
7239912 | Dobak, III | Jul 2007 | B2 |
7252090 | Goetz | Aug 2007 | B2 |
7260436 | Kilgore et al. | Aug 2007 | B2 |
7266412 | Stypulkowski | Sep 2007 | B2 |
7288062 | Spiegel | Oct 2007 | B2 |
7313440 | Miesel | Dec 2007 | B2 |
7324852 | Barolat et al. | Jan 2008 | B2 |
7326181 | Katims | Feb 2008 | B2 |
7333857 | Campbell | Feb 2008 | B2 |
7337005 | Kim et al. | Feb 2008 | B2 |
7346398 | Gross et al. | Mar 2008 | B2 |
7349743 | Tadlock | Mar 2008 | B2 |
RE40279 | Sluijter et al. | Apr 2008 | E |
7359751 | Erickson et al. | Apr 2008 | B1 |
7363076 | Yun et al. | Apr 2008 | B2 |
7389145 | Kilgore et al. | Jun 2008 | B2 |
7393351 | Woloszko et al. | Jul 2008 | B2 |
7463927 | Chaouat | Dec 2008 | B1 |
7483747 | Gliner et al. | Jan 2009 | B2 |
7493172 | Whitehurst et al. | Feb 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7571007 | Erickson et al. | Aug 2009 | B2 |
7580753 | Kim et al. | Aug 2009 | B2 |
7599737 | Yomtov et al. | Oct 2009 | B2 |
7634317 | Ben-David et al. | Dec 2009 | B2 |
7676269 | Yun et al. | Mar 2010 | B2 |
7689276 | Dobak | Mar 2010 | B2 |
7689289 | King | Mar 2010 | B2 |
7715915 | Rye et al. | May 2010 | B1 |
7734340 | De Ridder | Jun 2010 | B2 |
7734355 | Cohen et al. | Jun 2010 | B2 |
7742810 | Moffitt et al. | Jun 2010 | B2 |
7761170 | Kaplan et al. | Jul 2010 | B2 |
7778704 | Rezai | Aug 2010 | B2 |
7792591 | Rooney et al. | Sep 2010 | B2 |
7801604 | Brockway et al. | Sep 2010 | B2 |
7813803 | Heruth et al. | Oct 2010 | B2 |
7826901 | Lee et al. | Nov 2010 | B2 |
7853322 | Bourget et al. | Dec 2010 | B2 |
7860570 | Whitehurst et al. | Dec 2010 | B2 |
7865243 | Whitehurst et al. | Jan 2011 | B1 |
7877136 | Moffitt et al. | Jan 2011 | B1 |
7877146 | Rezai | Jan 2011 | B2 |
7881805 | Bradley | Feb 2011 | B2 |
7890176 | Jaax et al. | Feb 2011 | B2 |
7890182 | Parramon et al. | Feb 2011 | B2 |
7914452 | Hartley et al. | Mar 2011 | B2 |
7933654 | Merfeld et al. | Apr 2011 | B2 |
7937145 | Dobak | May 2011 | B2 |
8000794 | Lozano | Aug 2011 | B2 |
8010198 | Libbus et al. | Aug 2011 | B2 |
8027718 | Spinner et al. | Sep 2011 | B2 |
8046075 | Rezai | Oct 2011 | B2 |
8060208 | Kilgore et al. | Nov 2011 | B2 |
8082039 | Kim et al. | Dec 2011 | B2 |
8150531 | Skelton | Apr 2012 | B2 |
8170658 | Dacey et al. | May 2012 | B2 |
8170675 | Alataris et al. | May 2012 | B2 |
8209021 | Alataris et al. | Jun 2012 | B2 |
8209028 | Skelton et al. | Jun 2012 | B2 |
8224453 | De Ridder | Jul 2012 | B2 |
8224459 | Pianca et al. | Jul 2012 | B1 |
8255048 | Dal Molin et al. | Aug 2012 | B2 |
8280515 | Greenspan et al. | Oct 2012 | B2 |
8301241 | Ternes et al. | Oct 2012 | B2 |
8340775 | Cullen et al. | Dec 2012 | B1 |
8355792 | Alataris et al. | Jan 2013 | B2 |
8359102 | Alataris et al. | Jan 2013 | B2 |
8359103 | Alataris et al. | Jan 2013 | B2 |
8364271 | De Ridder | Jan 2013 | B2 |
8364273 | De Ridder | Jan 2013 | B2 |
2622601 | Alataris et al. | Mar 2013 | A1 |
8396559 | Alataris et al. | Mar 2013 | B2 |
8412338 | Faltys | Apr 2013 | B2 |
8423147 | Alataris et al. | Apr 2013 | B2 |
8428735 | Littlewood et al. | Apr 2013 | B2 |
8428748 | Alataris et al. | Apr 2013 | B2 |
8467875 | Bennett et al. | Jun 2013 | B2 |
8483830 | Tweden | Jul 2013 | B2 |
8569935 | Kosierkiewicz | Oct 2013 | B1 |
8577458 | Libbus et al. | Nov 2013 | B1 |
8612018 | Gillbe | Dec 2013 | B2 |
8649874 | Alataris et al. | Feb 2014 | B2 |
8666506 | King | Mar 2014 | B2 |
8688212 | Libbus et al. | Apr 2014 | B2 |
8691877 | Yun et al. | Apr 2014 | B2 |
8712533 | Alataris | Apr 2014 | B2 |
8751009 | Wacnik | Jun 2014 | B2 |
8768469 | Tweden et al. | Jul 2014 | B2 |
8768472 | Fang | Jul 2014 | B2 |
8805512 | Greiner et al. | Aug 2014 | B1 |
8825164 | Tweden et al. | Sep 2014 | B2 |
8825166 | John | Sep 2014 | B2 |
8886326 | Alataris et al. | Nov 2014 | B2 |
8886328 | Alataris et al. | Nov 2014 | B2 |
8892209 | Alataris et al. | Nov 2014 | B2 |
8918172 | Moffitt et al. | Dec 2014 | B2 |
8918190 | Libbus et al. | Dec 2014 | B2 |
8918191 | Libbus et al. | Dec 2014 | B2 |
8923964 | Libbus et al. | Dec 2014 | B2 |
8923990 | Libbus et al. | Dec 2014 | B2 |
8965521 | Birkholz et al. | Feb 2015 | B2 |
8996125 | Greiner et al. | Mar 2015 | B2 |
9002457 | Hamann et al. | Apr 2015 | B2 |
9002459 | Lee et al. | Apr 2015 | B2 |
9026214 | Ternes et al. | May 2015 | B2 |
9026215 | Rossing | May 2015 | B2 |
9026226 | Gerber et al. | May 2015 | B2 |
9067076 | Nolan et al. | Jun 2015 | B2 |
9101770 | Arcot-Krishnamurthy et al. | Aug 2015 | B2 |
9126044 | Kramer et al. | Sep 2015 | B2 |
9132272 | Alves et al. | Sep 2015 | B2 |
9180298 | Alataris et al. | Nov 2015 | B2 |
9205258 | Simon et al. | Dec 2015 | B2 |
9211410 | Levine et al. | Dec 2015 | B2 |
9295840 | Thacker | Mar 2016 | B1 |
9308370 | Lima et al. | Apr 2016 | B2 |
9327121 | Bertram | May 2016 | B2 |
9327127 | Alataris et al. | May 2016 | B2 |
9370659 | Franke et al. | Jun 2016 | B2 |
9381356 | Parker | Jul 2016 | B2 |
9403007 | Moekelke et al. | Aug 2016 | B2 |
9421355 | Colborn | Aug 2016 | B2 |
9440074 | Ternes et al. | Sep 2016 | B2 |
9480846 | Strother | Nov 2016 | B2 |
9533153 | Libbus et al. | Jan 2017 | B2 |
9561366 | Wei et al. | Feb 2017 | B2 |
9561370 | Rezai | Feb 2017 | B2 |
9572983 | Levine et al. | Feb 2017 | B2 |
9694183 | Grandhe | Jul 2017 | B2 |
9724509 | Su et al. | Aug 2017 | B2 |
9724511 | Wei et al. | Aug 2017 | B2 |
9833614 | Gliner | Dec 2017 | B1 |
9895532 | Kaula et al. | Feb 2018 | B2 |
9895539 | Heit et al. | Feb 2018 | B1 |
9913980 | Ostroff et al. | Mar 2018 | B2 |
9950173 | Doan | Apr 2018 | B2 |
9968732 | Drew et al. | May 2018 | B2 |
10188856 | Libbus et al. | Jan 2019 | B1 |
10207110 | Gelfand | Feb 2019 | B1 |
10220205 | Bhadra et al. | Mar 2019 | B2 |
10328264 | Hamann et al. | Jun 2019 | B2 |
10485975 | Greiner et al. | Nov 2019 | B2 |
10493275 | Alataris | Dec 2019 | B2 |
10561845 | Giftakis et al. | Feb 2020 | B2 |
10632300 | Wagenbach et al. | Apr 2020 | B2 |
10675468 | Torgerson | Jun 2020 | B2 |
10898714 | Libbus et al. | Jan 2021 | B2 |
11045649 | Wei et al. | Jun 2021 | B2 |
20020055779 | Andrews | May 2002 | A1 |
20020087201 | Firlik et al. | Jul 2002 | A1 |
20020128700 | Cross | Sep 2002 | A1 |
20030100931 | Mullett | May 2003 | A1 |
20030120323 | Meadows et al. | Jun 2003 | A1 |
20030135248 | Stypulkowski | Jul 2003 | A1 |
20040015202 | Chandler et al. | Jan 2004 | A1 |
20040034394 | Woods et al. | Feb 2004 | A1 |
20040039425 | Greenwood-Van Meerveld | Feb 2004 | A1 |
20040059395 | North et al. | Mar 2004 | A1 |
20040073273 | Gluckman et al. | Apr 2004 | A1 |
20040093093 | Andrews | May 2004 | A1 |
20040116977 | Finch et al. | Jun 2004 | A1 |
20040122477 | Whitehorse | Jun 2004 | A1 |
20040158298 | Gliner | Aug 2004 | A1 |
20040162590 | Whitehurst et al. | Aug 2004 | A1 |
20040167584 | Carroll et al. | Aug 2004 | A1 |
20040186532 | Tadlock | Sep 2004 | A1 |
20040193228 | Gerber | Sep 2004 | A1 |
20040210270 | Erickson | Oct 2004 | A1 |
20040210271 | Campen et al. | Oct 2004 | A1 |
20040267330 | Lee et al. | Dec 2004 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050033381 | Carter et al. | Feb 2005 | A1 |
20050038489 | Grill | Feb 2005 | A1 |
20050060001 | Singhal et al. | Mar 2005 | A1 |
20050070982 | Heruth et al. | Mar 2005 | A1 |
20050113877 | Spinelli et al. | May 2005 | A1 |
20050113878 | Gerber | May 2005 | A1 |
20050113882 | Cameron et al. | May 2005 | A1 |
20050119713 | Whitehurst et al. | Jun 2005 | A1 |
20050143783 | Boveja | Jun 2005 | A1 |
20050143789 | Whitehurst et al. | Jun 2005 | A1 |
20050149148 | King | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154435 | Stern et al. | Jul 2005 | A1 |
20050222641 | Pless | Oct 2005 | A1 |
20050240241 | Yun et al. | Oct 2005 | A1 |
20050245978 | Varrichio et al. | Nov 2005 | A1 |
20050245987 | Woods | Nov 2005 | A1 |
20050246006 | Daniels | Nov 2005 | A1 |
20050267545 | Cory | Dec 2005 | A1 |
20050278000 | Strother et al. | Dec 2005 | A1 |
20050288721 | Girouard | Dec 2005 | A1 |
20060004422 | De Ridder | Jan 2006 | A1 |
20060009820 | Royle | Jan 2006 | A1 |
20060015153 | Gliner et al. | Jan 2006 | A1 |
20060030895 | Simon et al. | Feb 2006 | A1 |
20060041285 | Johnson | Feb 2006 | A1 |
20060074456 | Pyles et al. | Apr 2006 | A1 |
20060079937 | King et al. | Apr 2006 | A1 |
20060095088 | De Ridder | May 2006 | A1 |
20060100671 | Ridder | May 2006 | A1 |
20060149337 | John | Jul 2006 | A1 |
20060161219 | Mock et al. | Jul 2006 | A1 |
20060161235 | King | Jul 2006 | A1 |
20060167525 | King | Jul 2006 | A1 |
20060168805 | Hegland et al. | Aug 2006 | A1 |
20060190044 | Libbus et al. | Aug 2006 | A1 |
20060190048 | Gerber | Aug 2006 | A1 |
20060224187 | Bradley et al. | Oct 2006 | A1 |
20060229687 | Goetz et al. | Oct 2006 | A1 |
20060253182 | King | Nov 2006 | A1 |
20060271108 | Libbus et al. | Nov 2006 | A1 |
20070021803 | Deem et al. | Jan 2007 | A1 |
20070032827 | Katims | Feb 2007 | A1 |
20070039625 | Heruth et al. | Feb 2007 | A1 |
20070043400 | Donders et al. | Feb 2007 | A1 |
20070049988 | Carbunaru | Mar 2007 | A1 |
20070049991 | Klostermann et al. | Mar 2007 | A1 |
20070060954 | Cameron et al. | Mar 2007 | A1 |
20070066997 | He et al. | Mar 2007 | A1 |
20070073353 | Rooney et al. | Mar 2007 | A1 |
20070073354 | Knudson et al. | Mar 2007 | A1 |
20070083240 | Peterson et al. | Apr 2007 | A1 |
20070100388 | Gerber | May 2007 | A1 |
20070106337 | Errico et al. | May 2007 | A1 |
20070106342 | Schumann | May 2007 | A1 |
20070150029 | Bourget et al. | Jun 2007 | A1 |
20070150034 | Rooney et al. | Jun 2007 | A1 |
20070156183 | Rhodes | Jul 2007 | A1 |
20070156201 | Rossing | Jul 2007 | A1 |
20070167992 | Carley | Jul 2007 | A1 |
20070179559 | Giftakis et al. | Aug 2007 | A1 |
20070179579 | Feler et al. | Aug 2007 | A1 |
20070191902 | Errico | Aug 2007 | A1 |
20070203537 | Goetz et al. | Aug 2007 | A1 |
20070213789 | Nolan et al. | Sep 2007 | A1 |
20070239226 | Overstreet | Oct 2007 | A1 |
20070244522 | Overstreet | Oct 2007 | A1 |
20070255118 | Miesel et al. | Nov 2007 | A1 |
20070265681 | Gerber et al. | Nov 2007 | A1 |
20070293893 | Stolen et al. | Dec 2007 | A1 |
20070299482 | Littlewood et al. | Dec 2007 | A1 |
20080033511 | Dobak | Feb 2008 | A1 |
20080065158 | Ben-Ezra | Mar 2008 | A1 |
20080086036 | Hartley | Apr 2008 | A1 |
20080097539 | Belalcazar | Apr 2008 | A1 |
20080103570 | Gerber | May 2008 | A1 |
20080167697 | Johnson | Jul 2008 | A1 |
20080183259 | Bly et al. | Jul 2008 | A1 |
20080234791 | Arle et al. | Sep 2008 | A1 |
20080269854 | Hegland et al. | Oct 2008 | A1 |
20080281381 | Gerber et al. | Nov 2008 | A1 |
20080300449 | Gerber | Dec 2008 | A1 |
20080319511 | Pless | Dec 2008 | A1 |
20090018617 | Skelton et al. | Jan 2009 | A1 |
20090024187 | Erickson et al. | Jan 2009 | A1 |
20090036945 | Chancellor et al. | Feb 2009 | A1 |
20090054962 | Lefler et al. | Feb 2009 | A1 |
20090069803 | Starkebaum | Mar 2009 | A1 |
20090076565 | Surwit | Mar 2009 | A1 |
20090083070 | Giftakis | Mar 2009 | A1 |
20090112282 | Kast et al. | Apr 2009 | A1 |
20090118777 | Iki | May 2009 | A1 |
20090125079 | Armstrong et al. | May 2009 | A1 |
20090132010 | Kronberg | May 2009 | A1 |
20090132016 | Putz | May 2009 | A1 |
20090157141 | Chiao et al. | Jun 2009 | A1 |
20090157149 | Wahlgren et al. | Jun 2009 | A1 |
20090196472 | Goetz et al. | Aug 2009 | A1 |
20090198306 | Goetz et al. | Aug 2009 | A1 |
20090204173 | Fang et al. | Aug 2009 | A1 |
20090204192 | Carlton et al. | Aug 2009 | A1 |
20090281595 | King et al. | Nov 2009 | A1 |
20090287274 | De Ridder | Nov 2009 | A1 |
20090287279 | Parramon et al. | Nov 2009 | A1 |
20090326611 | Gillbe | Dec 2009 | A1 |
20100010567 | Deem et al. | Jan 2010 | A1 |
20100016929 | Prochazka | Jan 2010 | A1 |
20100036454 | Bennett et al. | Feb 2010 | A1 |
20100042193 | Slavin | Feb 2010 | A1 |
20100057178 | Simon | Mar 2010 | A1 |
20100094375 | Donders et al. | Apr 2010 | A1 |
20100125313 | Lee et al. | May 2010 | A1 |
20100137938 | Kishawi et al. | Jun 2010 | A1 |
20100152817 | Gillbe | Jun 2010 | A1 |
20100191307 | Fang et al. | Jul 2010 | A1 |
20100241190 | Kilgore et al. | Sep 2010 | A1 |
20100249875 | Kishawi et al. | Sep 2010 | A1 |
20100256696 | Schleicher et al. | Oct 2010 | A1 |
20100274312 | Alataris et al. | Oct 2010 | A1 |
20100274314 | Alataris et al. | Oct 2010 | A1 |
20100274315 | Alataris et al. | Oct 2010 | A1 |
20100274316 | Alataris et al. | Oct 2010 | A1 |
20100274317 | Parker et al. | Oct 2010 | A1 |
20100274318 | Walker et al. | Oct 2010 | A1 |
20100274320 | Torgerson | Oct 2010 | A1 |
20100274326 | Chitre et al. | Oct 2010 | A1 |
20100324630 | Lee et al. | Dec 2010 | A1 |
20100331916 | Parramon et al. | Dec 2010 | A1 |
20110009919 | Carbunaru et al. | Jan 2011 | A1 |
20110009923 | Lee | Jan 2011 | A1 |
20110009927 | Parker et al. | Jan 2011 | A1 |
20110022114 | Navarro | Jan 2011 | A1 |
20110040291 | Weissenrieder-Norlin et al. | Feb 2011 | A1 |
20110184301 | Holmstrom et al. | Jul 2011 | A1 |
20110184486 | De Ridder | Jul 2011 | A1 |
20110184488 | De Ridder | Jul 2011 | A1 |
20110201977 | Tass | Aug 2011 | A1 |
20110276107 | Simon et al. | Nov 2011 | A1 |
20110282412 | Glukhovsky et al. | Nov 2011 | A1 |
20120010680 | Wei | Jan 2012 | A1 |
20120016437 | Alataris et al. | Jan 2012 | A1 |
20120016438 | Alataris et al. | Jan 2012 | A1 |
20120016439 | Alataris et al. | Jan 2012 | A1 |
20120089200 | Ranu et al. | Apr 2012 | A1 |
20120150252 | Feldman et al. | Jun 2012 | A1 |
20120203304 | Alataris et al. | Aug 2012 | A1 |
20120209349 | Alataris et al. | Aug 2012 | A1 |
20120277833 | Gerber et al. | Nov 2012 | A1 |
20120283797 | De Ridder | Nov 2012 | A1 |
20130006325 | Woods et al. | Jan 2013 | A1 |
20130023951 | Greenspan | Jan 2013 | A1 |
20130041425 | Fang et al. | Feb 2013 | A1 |
20130066411 | Thacker et al. | Mar 2013 | A1 |
20130079841 | Su | Mar 2013 | A1 |
20130096643 | Fang et al. | Apr 2013 | A1 |
20130096644 | Fang et al. | Apr 2013 | A1 |
20130110196 | Alataris et al. | May 2013 | A1 |
20130123879 | Alataris et al. | May 2013 | A1 |
20130172955 | Alataris | Jul 2013 | A1 |
20130204173 | Kelly et al. | Aug 2013 | A1 |
20130204320 | Alataris et al. | Aug 2013 | A1 |
20130204321 | Alataris et al. | Aug 2013 | A1 |
20130204322 | Alataris et al. | Aug 2013 | A1 |
20130204323 | Thacker et al. | Aug 2013 | A1 |
20130204324 | Thacker | Aug 2013 | A1 |
20130204338 | Alataris et al. | Aug 2013 | A1 |
20130211487 | Fang et al. | Aug 2013 | A1 |
20130237948 | Donders | Sep 2013 | A1 |
20130238047 | Libbus et al. | Sep 2013 | A1 |
20130261695 | Thacker et al. | Oct 2013 | A1 |
20130261696 | Alataris et al. | Oct 2013 | A1 |
20130261697 | Alataris et al. | Oct 2013 | A1 |
20130289659 | Nelson | Oct 2013 | A1 |
20140031896 | Alataris et al. | Jan 2014 | A1 |
20140142656 | Alataris et al. | May 2014 | A1 |
20140142657 | Alataris et al. | May 2014 | A1 |
20140142658 | Alataris et al. | May 2014 | A1 |
20140142659 | Alataris et al. | May 2014 | A1 |
20140142673 | Alataris et al. | May 2014 | A1 |
20140296936 | Alataris et al. | Oct 2014 | A1 |
20140316484 | Edgerton | Oct 2014 | A1 |
20140343622 | Alataris et al. | Nov 2014 | A1 |
20140379044 | Walker et al. | Dec 2014 | A1 |
20150012079 | Goroszeniuk et al. | Jan 2015 | A1 |
20150018896 | Alataris et al. | Jan 2015 | A1 |
20150032181 | Baynham | Jan 2015 | A1 |
20150032182 | Alataris et al. | Jan 2015 | A1 |
20150032183 | Alataris et al. | Jan 2015 | A1 |
20150039040 | Cowan et al. | Feb 2015 | A1 |
20150039049 | Alataris et al. | Feb 2015 | A1 |
20150039050 | Alataris et al. | Feb 2015 | A1 |
20150045853 | Alataris et al. | Feb 2015 | A1 |
20150045854 | Alataris et al. | Feb 2015 | A1 |
20150051664 | Alataris et al. | Feb 2015 | A1 |
20150051665 | Hershey et al. | Feb 2015 | A1 |
20150073510 | Perryman | Mar 2015 | A1 |
20150217116 | Parramon et al. | Aug 2015 | A1 |
20150343220 | Alataris et al. | Dec 2015 | A1 |
20160114165 | Levine et al. | Apr 2016 | A1 |
20160121119 | Alataris et al. | May 2016 | A1 |
20160256689 | Vallejo et al. | Sep 2016 | A1 |
20160263376 | Yoo et al. | Sep 2016 | A1 |
20160287872 | Alataris et al. | Oct 2016 | A1 |
20160287873 | Alataris et al. | Oct 2016 | A1 |
20160287874 | Alataris et al. | Oct 2016 | A1 |
20160287875 | Thacker et al. | Oct 2016 | A1 |
20160287888 | Alataris et al. | Oct 2016 | A1 |
20160303374 | Alataris et al. | Oct 2016 | A1 |
20160339239 | Yoo et al. | Nov 2016 | A1 |
20170050021 | Cosman, Sr. | Feb 2017 | A1 |
20170087369 | Bokil | Mar 2017 | A1 |
20170095669 | Libbus et al. | Apr 2017 | A1 |
20170165485 | Sullivan et al. | Jun 2017 | A1 |
20170209699 | Thacker | Jul 2017 | A1 |
20170216602 | Waataja et al. | Aug 2017 | A1 |
20170239470 | Wei et al. | Aug 2017 | A1 |
20170274209 | Edgerton | Sep 2017 | A1 |
20170348526 | Southwell | Dec 2017 | A1 |
20180110561 | Levin | Apr 2018 | A1 |
20180256906 | Pivonka | Sep 2018 | A1 |
20180272132 | Subbaroyan | Sep 2018 | A1 |
20190290900 | Esteller | Sep 2019 | A1 |
20190321641 | Baldoni | Oct 2019 | A1 |
20200139138 | Sit | May 2020 | A1 |
Number | Date | Country |
---|---|---|
101175530 | May 2008 | CN |
10318071 | Nov 2004 | DE |
1181947 | Feb 2002 | EP |
2243511 | Oct 2010 | EP |
2448633 | May 2012 | EP |
2630984 | Aug 2013 | EP |
2449546 | Nov 2008 | GB |
2002200179 | Jul 2002 | JP |
2007528774 | Oct 2007 | JP |
2008500086 | Jan 2008 | JP |
1512625 | Oct 1989 | SU |
1690727 | Nov 1991 | SU |
WO-02065896 | Aug 2002 | WO |
WO-02092165 | Nov 2002 | WO |
WO-03015863 | Feb 2003 | WO |
WO-03066154 | Aug 2003 | WO |
WO-2004007018 | Jan 2004 | WO |
WO-2005115532 | Dec 2005 | WO |
WO-2006007048 | Jan 2006 | WO |
WO-2006057734 | Jun 2006 | WO |
WO-2006063458 | Jun 2006 | WO |
WO-2006084635 | Aug 2006 | WO |
WO-2006119046 | Nov 2006 | WO |
WO-2007035925 | Mar 2007 | WO |
WO-2007082382 | Jul 2007 | WO |
WO-2007103324 | Sep 2007 | WO |
WO-2007117232 | Oct 2007 | WO |
WO-2008039982 | Apr 2008 | WO |
WO-2008045434 | Apr 2008 | WO |
WO-2008106174 | Sep 2008 | WO |
WO-2008121891 | Oct 2008 | WO |
WO-2008140940 | Nov 2008 | WO |
WO-2008142402 | Nov 2008 | WO |
WO-2008153726 | Dec 2008 | WO |
WO-2009018518 | Feb 2009 | WO |
WO-2009061813 | May 2009 | WO |
WO-2009097224 | Aug 2009 | WO |
WO-20090129329 | Oct 2009 | WO |
WO-2010111358 | Sep 2010 | WO |
WO-2011014570 | Feb 2011 | WO |
WO-2012154985 | Nov 2012 | WO |
WO-2016154091 | Sep 2016 | WO |
WO-2017044904 | Mar 2017 | WO |
WO-2017146658 | Aug 2017 | WO |
Entry |
---|
Cadish, “Stimulation Latency and Comparison of Cycling Regimens in Women Using Sacral Neuromodulation,” Feb. 1, 2016, 4 pages. |
Siegel et al., “Prospective Randomized Feasibility Study Assessing the Effect of Cyclic Sacral Neuromodulation on Urinary Urge Incontinence in Women,” Female Pelvic Med Reconstr Surg. 2018, 5 pages. |
European Extended Search Report for European Patent Application No. 17744784.4, Applicant: Nevro Corporation, dated Oct. 8, 2019, 9 pages. |
International Search Report and Written Opinion for International Patent Application No. PCT/2017/014784, dated May 1, 2017, 13 pages. |
U.S. Appl. No. 14/534,769, filed Nov. 6, 2014, Park. |
U.S. Appl. No. 15/606,869, filed May 26, 2017, Lee. |
Abejon et al., “Is Impedance a Parameter to be Taken into Account in Spinal Cord Stimulation?” Pain Physician, 2007, 8 pages. |
Agnew et al., “Considerations for safety with chronically implanted nerve electrodes,” Epilepsia, 31.s2, 1990, 6 pages. |
Al-Kaisy et al., “10 kHz High-Frequency Spinal Cord Stimulation for Chronic Axial Low Back Pain in Patients With No History of Spinal Surgery: A Preliminary, Prospective, Open Label and Proof-of-Concept Study,” Neuromodulation: Technology at the Neural Interface, 2016, 8 pages. |
Al-Kaisy et al., “Prospective, Randomized, Sham-Control, Double Blind, Crossover Trial of Subthreshold Spinal Cord Stimulation at Various Kilohertz Frequencies in Subjects Suffering from Failed Back Surgery Syndrome,” International Neuromodulation Society, 2018, 9 pages. |
Al-Kaisy et al., “The Use of 10-Kilohertz Spinal Cord Stimulation in a Cohort of Patients with Chronic Neuropathic Limb Pain Refractory to Medical Management,” Neuromodulation Technology at the Neural, Interface, 2015, 6 pages. |
Al-Kaisy et al., Poster: “High-Frequency Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Back Pain Patients without Prior Back Surgery,” 1 page. |
Alo et al., “Factors Affecting Impedance of Percutaneous Leads in Spinal Cord Stimulation,” International Neuromodulation Society, vol. 9, No. 2, 2006, 8 pages. |
Alo et al., “New Trends in Neuromodulation for the Management of Neuropathic Pain,” Neurosurgery, vol. 50, No. 4, Apr. 2002, 15 pages. |
Bara et al., Poster re: High Frequency Spinal Cord Stimulation for Dominant Back Pain—1 year follow up, 2013, 1 page. |
Bennett et al., “Spinal Cord Stimulation for Complex regional pain syndrome I [RSD]: a Retrospective Multicenter Experience from 1995 to 1998 of 101 patients.” Neuromodulation, vol. 2, No. 3, 1999, 9 pages. |
BionicNAVIGATOR Software Guide, Part MP9055261-001, 2004, 58 pages. |
Bronstein et al., “The Rationale Driving the Evolution of Deep Brain Stimulation of Constant-Current Devices,” International Neuromodulation Society 2014, 5 pages. |
Broseta et al., “High-Frequency cervical spinal cord stimulation in spasticity and motor disorders,” Advances in Stereotactic and Functional Neurosurgery 7. Springer Verlag 1987, 6 pages. |
Cahana et al., “Acute Differential Modulation of Synaptic Transmission and Cell Survival During Exposure to Pulsed and Continuous Radiofrequency Energy,” Journal of Pain, vol. 4, No. 4, May 2003, 6 pages. |
Cameron et al., “Effects of posture on stimulation parameters in spinal cord stimulation,” Neuromodulation: Technology at the Neural Interface 1.4, 1998, 8 pages. |
Camilleri et al., “Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device,” Surgery 143.6, 2008, 9 pages. |
Crapanzano et al., “High Frequency Spinal Cord Stimulation for Complex Regional Pain Syndrome: A Case Report,” Pain Physician, 2017, 6 pages. |
Cuellar et al., “Effect of High Frequency Alternating Current on Spinal Afferent Nociceptive Transmission,” Neuromodulation: Technology at the Neural Interface, 2012, 10 pages. |
De Carolis et al., Poster: “Efficacy of Spinal Cord Stimulation (SCS) in the Treatment of Failed Back Surgery Syndrome (FBSS): a comparative study,” 2013, 1 page. |
De Ridder et al., U.S. Appl. No. 60/895,061, Applicant: Dirk De Ridder, filed Mar. 15, 2007, 47 pages. |
Declaration of Dr. Jonathan Miller on behalf of European Patent No. 2853285, 26 pages, May 16, 2017. |
Duyvendak et al., “Spinal Cord Stimulation With a Dual Quadripolar Surgical Lead Placed in General Anesthesia is Effective in Treating Intractable Low Back and Leg Pain,” Neuromodulation: Technology at the Neural Interface, vol. 10, No. 2, 2007, 7 pages. |
Geddes, “A Short History of the electrical stimulation of excitable tissue—Including Electrotherapeutic Applications,” The Physiologist, vol. 27, No. 1, Feb. 1984, 51 pages. |
Gulve et al., Poster: “10kHz High Frequency Spinal Cord Stimulation: Middlesbrough Experience,” 2013, 1 page. |
Higuchi et al., “Exposure of the Dorsal Root Ganglion in Rats to Pulsed Radiofrequency Currents Activates Dorsal Horn Lamina I and II Neurons,” Neurosurgery, vol. 50, No. 4, Apr. 2002, 7 pages. |
House et al., “Safety and Efficacy of the House/3M Cochlear Implant in Profoundly Deaf Adults,” Otolaryngologic Clinics of North America, vol. 19, No. 2, May 1986, 12 pages. |
International Neuromodulation Society 10th World Congress, Neuromodulation: Technology that Improves Patient Care, London, England, May 21-26, 2011, 385 pages. |
Jacques et al., “Development of a New Implantable Bio-Telestimulator,” Surg. Neurol., vol. 13, May 1980, 2 pages. |
Jezernik et al., “Electrical Stimulation for the Treatment of Bladder Dysfunction: Current Status and Future Possibilities,” Neurological Research, vol. 24, Jul. 2002, 18 pages. |
Kapural et al., “Comparison of 10-kHz High Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial,” Neurosurgery, vol. 79, No. 5, Nov. 2016, 11 pages. |
Lambru et al., “Safety and Efficacy of Cervical 10 kHz Spinal Cord Stimulation in Chronic Refractory Primary Headaches: A Retrospective Case Series,” The Journal of Headache and Pain, 2016, 8 pages. |
Mavoori et al., “An Autonomous implantable computer for neural recording and stimulation in unrestrained primates,” Journal of Neuroscience Methods, 2005, 7 pages. |
McCreery et al., “Charge Density and Charge Per Phase as Cofactors in Neural Injury Induced by Electrical Stimulation,” IEEE Transactions on Biomedical Engineering, vol. 37, No. 10, Oct. 1990, 6 pages. |
McCreery et al., “Damage in Peripheral Nerve from Continuous Electrical Stimulation: Comparison of Two Stimulus Waveforms,” Medical and Biological Engineering and Computing, Jan. 1992, 6 pages. |
McCreery et al., “Relationship between Stimulus Amplitude, Stimulus Frequency and Neural Damage During Electrical Stimulation of Sciatic Nerve of a Cat,” Medical and Biological Engineering and Computing, May 1995, 4 pages. |
Medtronic—Spinal Cord Stimulation (SCS) Patient Management Guidelines for Clinicians, 1999, 114 pages. |
Meyerson et al., Mechanisms of spinal cord stimulation in neuropathic pain, Neurological Research, vol. 22, Apr. 2000, 5 pages. |
Miller, Jonathan, “Parameters of Spinal Cord Stimulation and Their Role in Electrical Charge Delivery: A Review,” Neuromodulation: Technology at the Neural Interface, 2016, 12 pages. |
Mounaïm et al., “New Neurostimulation Strategy and Corresponding Implantable Device to Enhance Bladder Functions,” Biomedical Engineering Trends in Electronics, Communications and Software, Chapter 5, 2011, 15 pages. |
Mueller et al., “The MED-EL SONATATI 100 Cochlear Implant: An evaluation of its safety in adults and children,” Acta Oto-Laryngologica, vol. 131, No. 5, 2011, 8 pages. |
Nevro—Leadership Through Innovation, J. P. Morgan 36th Annual Healthcare Conference, Jan. 8, 2018, 21 pages. |
Nevro—Leadership Through Innovation, J. P. Morgan 36th Annual Healthcare Conference, Jan. 24, 2019, 2 pages. |
NIDCD-NIH 2011, Cochlear Implant Brochure, http://www.nidcd.nih.gov/health/hearing/pages/coch.aspx, Jun. 29, 2012, 2 pages. |
North et al., “Spinal Cord Stimulation With Interleaved Pulses: A Randomized, Controlled Trial,” vol. 10, No. 4, 2007, 9 pages. |
OHSIPP Summer Newsletter, The Official Newsletter for the Ohio Society of Interventional Pain Physicians, vol. 1 Ed. 2, Summer 2010, 8 pages. |
Paicius et al., “Peripheral Nerve Field Stimulation for the Treatment of Chronic Low Back Pain: Preliminary Results of Long-Term Follow-up: A Case Series,” Neuromodulation: Technology at the Neural Interface, vol. 10, No. 3, 2007, 12 pages. |
Precision—Physician System Handbook, Advanced Bionic Corporation, Part 9055253-0001, 2005, 92 pages. |
Precision—Physician Trail Kit Insert, Advanced Bionic Corporation, Part 9055258-0001, 2005, 2 pages. |
Precision Spinal Cord Stimulation—Charging System Insert, Advanced Bionic Corporation, Part 9055074-0001, 2004, 2 pages. |
Precision Spinal Cord Stimulation—Charging System, Advanced Bionic Corporation, Part 9055259-0001, 2004, 2 pages. |
Precision Spinal Cord Stimulation—Patient System Handbook, Advanced Bionic Corporation, Part 9055072-0001, 2004, 93 pages. |
Precision Spinal Cord Stimulation—Patient Trial Journal, Advanced Bionic Corporation, Part 9055260-0001, 2004, 10 pages. |
Precision Spinal Cord Stimulation—Physician Implant Manual, Advanced Bionic Corporation, Part 9055255-0001, 2005, 70 pages. |
Precision Spinal Cord Stimulation—Physician Implant Manual, Advanced Bionic Corporation, Part 9055100, 2004, 62 pages. |
Precision Spinal Cord Stimulation—Physician Lead Manual, Advanced Bionic Corporation, Part No. 9055183-001, May 2004, 31 pages. |
Precision Spinal Cord Stimulation—Physician Lead Manual, Advanced Bionic Corporation, Part 9055095, 2004, 62 pages. |
Precision Spinal Cord Stimulation—Physician Lead Manual, Advanced Bionic Corporation, Part 9055256-0001, 2005, 56 pages. |
Precision Spinal Cord Stimulation—Physician Trail Handbook, Advanced Bionic Corporation, Part 9055254-0001, 2005, 66 pages. |
Precision Spinal Cord Stimulation—Physician Trail Kit Model SC-7005, Part 9055066-001, Advanced Bionic Corporation, 2004, 2 pages. |
Precision Spinal Cord Stimulation—Remote Control Model SC-5200, Part 9055107-001, 2004, Advanced Bionic Corporation, 2 pages. |
Precision Spinal Cord Stimulation—Remote Control Model SC-5210, Advanced Bionic Corporation, Part 9055257-001, 2005, 2 pages. |
Precision Spinal Cord Stimulation System—Patient System Handbook, Advanced Bionic Corporation, Part No. 9055184-001, May 2004, 86 pages. |
Precision Spinal Cord Stimulation System, Patient Trial Handbook, Part 9055078, 2004, 74 pages. |
Pudenz et al., “Development of an Implantable Telestimulator,” Proc. 4th Ann. Nat'l Conf. Neuroelectric Soc., Mar. 10-12, 1971, 111-12 (Wulfsohn, Norman L. and Anthony Sances, Jr. (eds.) 1971, 4 pages. |
Pudenz et al., “Neural Stimulation: Clinical and Laboratory Experiences”, Surg. Neurol, 39:235-242 (1993). |
Rapcan et al., Clinical Study, “High-Frequency—Spinal Cord Stimulation,” Indexed and Abstracted in Science Citation Index Expanded and in Journal Citation Reports, 2015, 3 pages. |
Renew Neurostimulation System—Clinician's Manual—Advanced Neuromodulation Systems, Life Gets Better, 2000, 77 pages. |
Rosenblueth et al., “The Blocking and Deblocking Effects of Alternating Currents on Nerve,” Department of Physiology in Harvard Medical School, Nov. 1938, 13 pages. |
Schulman et al., “Battery Powered BION FES Network,” Proceedings of the 26th Annual Conference of the IEEE EMBS, San Francisco, CA., Sep. 1-5, 2004, 4 pages. |
Sharan et al., “Evolving Patterns of Spinal Cord Stimulation in Patients Implanted for Intractable Low Back and Leg Pain,” International Neuromodulation Society, vol. 5, No. 3, 2002, 13 pages. |
Shealy et al., “Dorsal col. Electrohypalgesia,” Jul. 1969, 8 pages. |
Shelden et al., “Depolarization in the Treatment of Trigeminal Neuralgia,” Evaluation of Compression and Electrical Methods, Clinical Concept of Neurophysiological Mechanism, 1966, 8 pages. |
Shelden et al., “Development and Clinical Capabilities of a New Implantable Biostimulator,” The American J. of Surgery, vol. 124, Aug. 1972, 6 pages. |
Shelden et al., Electrical Control of Facial Pain, Am. J. of Surgery, vol. 114, Aug. 1967, 6 pages. |
Shelden et al., “Electrical stimulation of the nervous system,” Surg. Neurol. vol. 4, No. 1, Jul. 1975, 6 pages. |
Smet et al.,., “Successful Treatment of Low Back Pain with a Novel Neuromodulation Device,” AZ Nikolaas, 12 pages. |
Smet et al., Poster: “High-Frequency Spinal Cord Stimulation at 10 kHz after Failed Traditional Spinal Cord Stimulation,” NANS, 2013, 1 page. |
St. Jude Medical, “Clinician's Manual—Percutaneous Lead Kit, Models 3143, 3146, 3149, 3153, 3156, 3159, 3183, 3186, 3189,” 2016, 24 pages. |
Struijk et al., “Recruitment of Dorsal Column Fibers in Spinal Cord Stimulation: Influence of Collateral Branching,” IEEE Transactions on Biomedical Engineering, vol. 39, No. 9, Sep. 1992, 10 pages. |
Taylor et al., “The Cross Effectiveness of Spinal Cord Stimulation in the Treatment of Pain: A Systematic Review of the Literature,” Journal of Pain and Symptom Management, vol. 27, No. 4., Apr. 2001, 9 pages. |
Thomson et al., “Effects of Rate on Analgesia in Kilohertz Frequency Spinal Cord Stimulation: Results of the PROCO Randomized Controlled Trial,” Neuromodulation: Technology at the Neural Interface, 2017, 10 pages. |
Tiede et al., “Novel Spinal Cord Stimulation Parameters in Patients with Predominate Back Pain,” Neuromodulation: Technology at the Neural Interface, 2013, 6 pages. |
Van Buyten et al., “High Frequency Spinal Cord Stimulation for the Treatment of Chronic Back Pain Patients: Results of a Prospective Multicenter European Clinical Study,” Neuromodulation Technology at the Neural Interface, International Neuromodulation Society, 2012, 8 pages. |
Van Buyten et al., “Pain Relief for Axial Back Pain Patients,” INS Meeting Poster, 1 page. |
Verrills et al., “Peripheral Nerve Field Stimulation for Chronic Pain: 100 Cases and Review of the Literature,” Pain Medicine, 2011, 11 pages. |
Verrills et al., “Salvaging Failed Neuromodulation Implants with Nevro High Frequency Spinal Cord System,” NANS Poster, 2013, 1 page. |
Von Korff et al., “Assessing Global Pain Severity by Self-Report in Clinical and Health Services Research,” SPINE, vol. 25, No. 24, 2000, 12 pages. |
Ward et al., “Electrical Stimulation Using Kilohertz-Frequency Alternating Current,” Journal of the American Physical Therapy Association, vol. 89, No. 2, Feb. 2009, 12 pages. |
Ward et al., “Variation in Motor Threshold with Frequency Using kHz Frequency Alternating Current,” Muscle and Nerve, Oct. 2001, 9 pages. |
Weinberg et al., “Increasing the oscillation frequency of strong magnetic fields above 101 kHz significantly raises peripheral nerve excitation thresholds,” Medical Physics Letter, May 2012, 6 pages. |
Wesselink et al., Analysis of Current Density and Related Parameters in Spinal Cord Stimulation, IEEE Transaction on Rehabilitation Engineering vol. 6, No. 2, Jun. 1998, 8 pages. |
Yearwood et al., “A Prospective Comparison of Spinal Cord Stimulation (SCS) Using Dorsal Column Stimulation (DCS), Intraspinal Nerve Root Stimulation (INRS), and Varying Pulse Width in the Treatment of Chronic Low Back Pain,” Congress of Neurological Surgeons 56th Annual Meeting, Oct. 7-12, 2006, 2 pages. |
Yearwood et al., “Pulse Width Programming in Spinal Cord Stimulation: A Clinical Study,” Pain Physician Journal, Jul./Aug. 2010, 16 pages. |
Yearwood et al., Case Reports: “A Prospective Comparison of Spinal Cord Stimulation (SCS) Using Dorsal Column Stimulation (DCS), Intraspinal Nerve Root Stimulation (INRS), and Varying Pulse Width in the Treatment of Chronic Low Back Pain,” Presented at the Congress of Neurological Surgeons 56th Annual Meeting, Oct. 7-12, 2006, 7 pages. |
Zhang et al., Changes Across Time in Spike Rate and Spike Amplitude of Auditory Nerve Fibers Stimulated by Electric Pulse Trains, Journal of the Association for Research of Otolaryngology, 2007, 17 pages. |
“The Need for Mechanism-Based Medicine in Neuromodulation,” Neuromodulation: Technology at the Neural Interface, 2012, 7 pages. |
Acticare.com website, http://web.archive.org/web/*/acticare.com, Internet Archive Way Back Machine, 2012, 22 pages. |
Advanced Neuromodulation Systems, Compustim SCS Systems, Clinical Manual, 1997, 52 pages. |
Al-Kaisy et al., “Sustained Effectiveness of 10kHz High-Frequency Spinal Cord Stimulation for Patients with Chronic, Low Back Pain: 24-month Results of Prospective Multicenter Study,” Pain Medicine, 2014, 8 pages. |
International Search Report and Written Opinion for International Patent Application No. PCT/US2017/014784, Applicant: Nevro Corp., dated May 1, 2017, 13 pages. |
Amendment in Response to Ex Parte Office Action for U.S. Appl. No. 13/446,970, First Named Inventor: Konstantinos Alataris, dated Nov. 28, 2012, 14 pages. |
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 13/245,450, First Named Inventor: Konstantinos Alataris, filed Feb. 7, 2012, 15 pages. |
Amendment in Response to Non-Final Office Action for U.S. Appl. No. 12/765,747, First Named Inventor: Konstantinos Alataris, dated Jan. 24, 2014, 21 pages. |
Applicant-Initiated Interview Summary for U.S. Appl. No. 13/245,450, First Named Inventor: Konstantinos Alataris, dated Feb. 1, 2012, 2 pages. |
Applicant-Initiated Interview Summary for U.S. Appl. No. 13/725,770, First Named Inventor: Konstantinos Alataris, dated Apr. 5, 2013, 3 pages. |
Applicant-Initiated Interview Summary for U.S. Appl. No. 12/765,747, First Named Inventor: Konstantinos Alataris, dated Sep. 11, 2013, 3 pages. |
Application Data Sheet for U.S. Appl. No. 13/446,970 (U.S. Pat. No. 8,359,102), First Named Inventor: Konstantinos Alataris, filed Apr. 13, 2012, 6 pages. |
Augustinsson et al., “Spinal Cord Stimulation in Cardiovascular Disease,” Functional Neurosurgery, vol. 6, No. 1, Jan. 1995, 10 pages. |
Barolat et al., “Multifactorial Analysis of Epidural Spinal Cord Stimulation,” Stereotactic and Functional Neurosurgery, 1991; 56: 77-103. |
Barolat et al., “Spinal Cord Stimulation for Chronic Pain Management,” Seminars in Neurosurgery, vol. 15, Nos. 2/3, 2004, 26 pages. |
Barolat et al., “Surgical Management of Pain—Spinal Cord Stimulation: Equipment and Implantation Techniques,” Chapter 41, Thieme Medical Publishers, New York, 2002, 11 pages. |
Benyamin et al., “A Case of Spinal Cord Stimulation in Raynaud's Phenomenon: Can Subthreshold Sensory Stimulation Have an Effect?” Pain Physician www.painphysicianjournal.com, 2007, 6 pages. |
Bhadra et al., “High Frequency electrical conduction block of the pudendal nerve,” Journal of Neural Engineering—Institute of Physics Publishing, 2006, 8 pages. |
Bhadra et al., Stimulation of High-Frequency Sinusoidal Electrical Block of Mammalian Myelinated Axons, J Comput Neurosci, 22:313-326, 2007. |
Bhadra MD, Niloy et al., “High-Frequency Electrical Conduction Block of Mammalian Peripheral Motor Nerve,” Muscle and Nerve, Dec. 2005, 9 pages. |
Boger et al., “Bladder Voiding by Combined High Frequency Electrical Pudendal Nerve Block and Sacral Root Stimulation,” Neurourology and Urodynamics, 27, 2008, 5 pages. |
Boston Scientific “Precision™ Spinal Cord Stimulator System Clinician Manual—Directions for Use,” 2015, 74 pages. |
Boston Scientific, News Release: “New Data Presented at NANS 2014 Demonstrate Long-Term, Low Back Pain Relief with Boston Scientific Precision Spectra™ Spinal Cord Stimulator System,” Dec. 12, 2014, 8 pages. |
Bowman and McNeal, Response of Single Alpha Motoneurons to High-Frequency Pulse Trains, Appl. Neurophysiol. 49, p. 121-138, 1986, 10 pages. |
Burton, Charles, “Dorsal Column Stimulation: Optimization of Application,” Surgical Neurology, vol. 4, No. 1, Jul. 1975, 10 pages. |
Butt et al., “Histological Findings Using Novel Stimulation Parameters in a Caprine Model,” European Journal of Pain Supplements, 2011, 2 pages. |
ClinicalTrials.gov, “Safety and Effectiveness Study of the Precision SCS System Adapted for High-Rate Spinal Cord Stimulation (ACCELERATE),” https://clinicaltrials.gov/ct2/show/NCT02093793?term=boston+scientific&recr=Open&cond=%22Pain%22&rank=3, Feb. 2015, 3 pages. |
Crosby et al., “Stimulation Parameters Define the Effectiveness of Burst Spinal Cord Stimulation in a Rat Model of Neuropathic Pain,” Neuromodulation Technology at the Neural Interface, International Neuromodulation Society, 2014, 8 pages. |
Curriculum Vitae and Declaration of Dr. Ganesan Baranidharan on behalf of European Patent No. 2630984, 19 pages, 2016. |
Curriculum Vitae and Declaration of Dr. Jonathan Miller on behalf of European Patent No. 2630984,42 pages, Oct. 25, 2016. |
Curriculum Vitae and Declaration of Dr. Simon James Thomson on behalf of European Patent No. 2630984, Oct. 24, 2016, 13 pages. |
Curriculum Vitae and Declaration of Prof. Bengt Linderoth on behalf of European Patent No. 2630984, Oct. 21, 2016, 6 pages. |
Curriculum Vitae of Michael A. Moffitt for European Patent No. 2630984, 2015, 2 pages. |
Declaration of Cameron C. McIntyre, Ph.D., May 6, 2015, 57 pages. |
Declaration of Cameron C. McIntyre, Ph.D., May 6, 2015, 88 pages. |
Declaration of M. Jason D. Rahn for European Patent No. 2243510, dated Feb. 2, 2017, 2 pages. |
Declaration of M. Jason D. Rahn, Jan. 7, 2015, 7 pages. |
Declaration of Prof. Bengt Linderoth for European Patent No. 2421600, dated Dec. 16, 2016 2 pages. |
DeRidder et al., “Are Paresthesias necessary for pain suppression in SCS—Burst Stimulation,” Brain, Brain Research Center Antwerp of Innovative and Interdisciplinary Neuromodulation, 2010, 27 pages. |
DeRidder et al., “Burst Spinal Cord Stimulation: Toward Paresthesia-Free Pain Suppression,” www.neurosurgery-online.com, vol. 66, Nos. 5, May 2010, 5 pages. |
Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition, “Paresthesia,” 1981, 4 pages. |
Doug Atkins of Medtronic Neurological, “Medtronic Neurostimulation Leads, 510(k) Summary,” Submission Prepared: Feb. 27, 2004, 6 pages. |
Eddicks et al., “Thoracic Spinal Cord Stimulation Improves Functional Status and Relieves Symptoms in Patients with Refractory Angina Pectoris: The First Placebo-Controlled Randomised Study,” Heart Journal, 2007, 6 pages. |
Ex Parte Office Action for U.S. Appl. No. 13/446,970, First Inventor Named: Konstantinos Alataris, dated Oct. 15, 2012, 9 pages. |
Feeling vs. Function Poster, Mager and Associates Consulting, 2009, 1 page. |
First Preliminary Amendment for U.S. Appl. No. 13/446,970, First Named Inventor: Konstantinos Alataris, dated May 18, 2012, 7 pages. |
Grill, Warren et al., “Stimulus Waveforms for Selective Neural Stimulation,” IEEE Engineering in Medicine and Biology, Jul./Aug. 1995, pp. 375-385. |
Guo et al., “Design and Implement of a Mini-Instrument for Rehabilitation with Transcutaneous Electrical Nerve Stimulation,” School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai China, Mar. 31, 2007, 5 pages. |
Hefferman et al., “Efficacy of Transcutaneous Spinal Electroanalgesia in Acute Postoperative Pain Management,” Anesthesiology, 2001, 2 pages. |
Hilberstadt et al., “The Effect of Transcutaneous Spinal Electroanalgesia upon Chronic Pain: A single case study,” Physiotherapy, vol. 86 No. 3, Mar. 2000, 2 pages. |
Holsheimer—Effectiveness of Spinal Cord Stimulation in the Management of Chronic Pain: Analysis of Technical Drawbacks and Solutions, Neurosurgery, vol. 40, No. 5, May 1997, pp. 990-999. |
Hopp et al., “Effect of anodal blockade of myelinated fibers on vagal c-fiber afferents,” American Journal Physiological Society, Nov. 1980; 239(5), 9 pages. |
Hoppenstein, Reuben, “Electrical Stimulation of the Ventral and Dorsal Columns of the Spinal Cord for Relief of Chronic Intractable Pain: Preliminary Report,” Surgical Neurology, vol. 4, No. 1, Jul. 1975, 9 pages. |
Huxely et al., “Excitation and Conduction in Nerve: Quantitative Analysis,” Science, Sep. 11, 1964; 145: 1154-9. |
J.P. Morgan North America Equity Research, “Nevro—Let the Launch Begin: Senza Approved, Raising PT to $54,” www.jpmorganmarkets.com, May 10, 2015, 8 pages. |
J.P. Morgan North America Equity Research, “Nevro—Welcome to the Future of Spinal Cord Stimulation Initiating at OW with $34 Price Target,” www.jpmorganmarkets.com, Dec. 1, 2014, 39 pages. |
Jain et al., Abstract—“Accelerate: A Prospective Multicenter Trial Evaluating the Use of High-Rate Spinal Cord Stimulation in the Management of Chronic Intractable Pain,” The American Academy of Pain Medicine, 2015, 1 page. |
Jang et al., “Analysis of Failed Spinal Cord Stimulation Trails in the Treatment of Intractable Chronic Pain,” J. Korean Neurosurg Soc 43, 2008, 5 pages. |
JMP Securities, “Nevro Corp. (NVRO) Initiating Coverage on Nevro Corp, with a Market Outperform Rating—Investment Highlights,” Dec. 1, 2014, 42 pages. |
Kapural et al., “Novel 10-Khz High Frequency Therapy (HF10 Therapy) is Superior to Traditional Low-Frequency Spinal Cord Stimulation for Treatment of Chronic Back and Leg Pain,” Anesthesiology The Journal of American Society of Anesthesiologists, Inc., 2015, 11 pages. |
Kilgore et al. “Nerve Conduction Block Utilizing High-Frequency Alternating Current” Medical & Biology Engineering and Computing, 2004, vol. 24, pp. 394-406. |
Kilgore et al. “Reversible Nerve Conduction Block Using Kilohertz Frequency Alternating Current,” Neuromodulation Technology at the Neural Interface, International Neuromodulation Society, 2013, 13 pages. |
Kreitler et al., “Chapter 15: Implantable Devices and Drug Delivery Systems—The Handbook for Chronic Pain,” NOVA Biomedical Books, New York, 2007, 17 pages. |
Krista Oakes of Neuromed, Inc., “Implanted Spinal Cord Stimulator Lead 510(k) Summary of Safety and Effectiveness,” Submission Prepared Feb. 21, 1996, 3 pages. |
Kuechmann et al., Abstract #853: “Could Automatic Position Adaptive Stimulation Be Useful in Spinal Cord Stimulation?” Medtronic, Inc., Minneapolis, MN, European Journal of Pain 13, 2009, 1 page. |
Kumar et al., “Spinal Cord Stimulation in Treatment of Chronic Benign Pain: Challenges in Treatment Planning and Present Status, a 22-Year Experience,” Neurosurgery, vol. 58, No. 3, Mar. 2006, 16 pages. |
Kumar et al., “The Effects of Spinal Cord Stimulation in Neuropathic Pain Are Sustained: A 24-month Follow-Up of the Prospective Randomized Controlled Multicenter Trial of the Effectiveness of Spinal Cord Stimulation,” www.neurosurgery-online.com, vol. 63, No. 4, Oct. 2008, 9 pages. |
Lempka et al., “Computational Analysis of Kilohertz Frequency Spinal Cord Stimulation for Chronic Pain Management,” Anesthesiology, vol. 122, No. 6, Jun. 2015, 15 pages. |
Linderoth et al., “Mechanisms of Spinal Cord Stimulation in Neuropathic and Ischemic Pain Syndromes,” Neuromodulation, Chapter 25, 2009, 19 pages. |
Linderoth et al., “Mechanisms of Spinal Cord Stimulation in Painful Syndromes: Role of Animal Models,” Pain Medicine, vol. 7, No. S1, 2006, 13 pages. |
Linderoth et al., “Physiology of Spinal Cord Stimulation: Review and Update,” Neuromodulation, vol. 2, No. 3, 1999, 15 pages. |
MacDonald, Alexander J. R, and Coates, Tim W., “The Discovery of Transcutaneous Spinal Electroanalgesia and Its Relief of Chronic Pain,” Physiotherapy, vol. 81. No. 11, Nov. 1995, 9 pages. |
Manola et al., “Technical Performance of Percutaneous Leads for Spinal Cord Stimulation: A Modeling Study,” International Neuromodulation Society, 2005, 12 pages. |
Mediati, R.D., “Mechanisms of Spinal Cord Stimulation,” Florence, Oct. 2, 2002, 31 pages. |
Medtronic—Neurological Division, QuadPlus, Model 3888, Lead Kit for Spinal Cord Stimulation (SCS) Implant Manual, 1996, 33 pages. |
Medtronic—Neurological Division, Resume II, Model 3587A, Lead Kit for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), Implant Manual, 1996, 32 pages. |
Medtronic commercial leaflet entitled: Surgical Lead Comparison, 1999, 4 pages. |
Medtronic, “Medtronic Pain Therapy—Using Neurostimulation for Chronic Pain, Information for Prescribers” 2007, 29 pages. |
Medtronic, Pain Therapy Product Guide, Dec. 2008, 31 pages. |
Medtronic, Pisces Quad 3487A, Pisces Quad Compact model 3887, Pisces Quad Plus 3888 Lead Kit, Implant Manual, 2008, 16 pages. |
Medtronic: Spinal Cord Stimulation Systems, 2013, 4 pages. |
Melzack, Ronald et al., “Pain Mechanisms: A New Theory,” Science, vol. 150, No. 3699, Nov. 19, 1965, 9 pages. |
Merriam Webster's Collegiate Dictionary, Tenth Edition, definition of “Implantable,” 1995, 3 pages. |
Miller, Jonathan, “Neurosurgery Survival Guide—A Comprehensive Guide to Neurosurgical Diagnosis and Treatment,” http://d3jonline.tripod.com/neurosurgery/, Nov. 14, 2016, 4 pages. |
Morgan Stanley Research North America, “Nevro Corp—There's Something Happening Here,” Dec. 15, 2014, 12 pages. |
Mosby's Medical Dictionary, 8th Edition, “Paresthesia,” 2009, 3 pages. |
Muller and Hunsperger, “Helvetica Physiologica et Pharmacologica Acta—Reversible Blockierung der Erregungsleitung im Nerven durch Mittelfrequenz—Daverstrom,” Schwabe & Co. Basel, vol. 25, Fasc. 1, 1967, 4 pages. |
Munglani, Rajesh, “The Longer Term Effect of Pulsed Radiofrequency for Neuropathic Pain,” Pain 80, 1999, 3 pages. |
Nashold et al., “Dorsal Column Stimulation for Control Pain—Preliminary Report on 30 Patients,” J. Neurosurg., vol. 36, May 1972, 8 pages. |
Nevro—Chronic Pain and Treatments, http://www.nevro.com/English/Patients/Chronic-Pain-and-Treatments/default.aspx, 2016, 3 pages. |
Nevro—Clinical Evidence www.nevro.com/English/Physicians/Clinical-Evidence/default.aspx, 2016, 2 pages. |
Nevro—HF10™ Therapy Fact Sheet, http://www.nevro.com/English/Newsroom/Resources/default.aspx, 2015, 4 pages. |
Nevro—Physician Overview, www.nevro.com/English/Physicians/Physician-Overview/default.aspx, 2016, 5 pages. |
Nevro—Senza System, http://www.nevro.com/English/Physicians/Senza-System/default.aspx, 2016, 3 pages. |
Nevro HF10 Therapy—New Hope for Chronic Back Pain and Leg Pain Sufferers, http://s21.q4cdn.com/478267292/files/doc_downloads/HF10-Therapy-New-Hope-for-Chronic-Pain.pdf, 2016, 2 pages. |
Nevro Observations and Response to Notice of Oppositions filed by Medtronic Inc., and Boston Scientific for European Patent No. 2207587, mailed Aug. 26, 2016, 16 pages. |
Nevro Response to Notice of Oppositions filed by Boston Scientific for European Patent No. 2421600, mailed Jul. 22, 2015, 16 pages. |
Nevro Response to Notice of Oppositions filed by Medtronic and Boston Scientific for European Patent No. 2630984, mailed Dec. 7, 2015, 26 pages. |
Nevro Response to Opposition of Division's Comments and Summons to Oral Proceedings for European Patent No. 2630984, mailed Oct. 25, 2016, 8 pages. |
Nevro Senza Patient Manual, Jan. 16, 2015, 53 pages. |
Nevro Senza Physician Implant Manual, Jan. 16, 2015, 31 pages. |
Nevro website: HF10 Therapy Advantages, www.nevro.com/English/Patients/HF10-Therapy-Advantages/default.aspx, 2016, 3 pages. |
Nevro Written Submissions and Response to Notice of Oppositions filed by Medtronic Inc., and Boston Scientific for European Patent No. 2243510, mailed Aug. 28, 2015, 17 pages. |
Nevro, PMA Approval Letter and Referenced Summary of Safety and Effectiveness Data (SSED) May 8, 2015, 60 pages. |
Nevro's Response to Further Submission by Medtronic, Inc., and Boston Scientific Neuromodulation Corporation for European Patent No. 2243510, mailed Feb. 24, 2017, 9 pages. |
Nevro's Response to Preliminary Opinion for Opposition by Medtronic, Inc., and Boston Scientific Neuromodulation Corporation for European Patent No. 2243510, dated Feb. 3, 2017, 36 pages. |
Nevro's presentation of HF10 therapy on Nevro's website, http://www.nevro.com/English/Home/default.aspx, 2016, 2 pages. |
Nevros Response to Opponent Submission of Declaration of Jonathan Miller in European Patent No. 2630984, mailed Nov. 18, 2016, 4 pages. |
News Release Details, “Nevro Corp. Announces Pricing of Initial Public Offering,” 2014, 1 page. |
Non-Final Office Action for U.S. Appl. No. 12/765,747, First Named Inventor: Konstantinos Alataris, dated Jul. 25, 2013, 7 pages. |
Non-Final Office Acton for U.S. Appl. No. 13/245,450, First Named Inventor: Konstantinos Alataris, dated Nov. 18, 2011, 11 pages. |
North American Neuromodulation Society—14th Annual Meeting, “Neuromodulation: Vision 2010,” Dec. 2-5, 2010, 9 pages. |
North American Neuromodulation Society—16th Annual Meeting, “From Innovation to Reality Syllabus,” Dec. 6-9, 2012, 198 pages. |
North American Neuromodulation Society—Celebrating 20 years, 18th Annual Meeting Program Book, Dec. 11-14, 2014, 28 pages. |
North American Neuromodulation Society, “Today's Vision, Tomorrow's Reality—17th Annual Meeting,” Dec. 5-8, 2013, 12 pages. |
North American Neuromodulation, “15th Annual Meeting, Our Crystal Anniversary,” Dec. 8-11, 2011, 8 pages. |
North et al., “Failed Back Surgery Syndrome: 5-year Follow-Up after Spinal; Cord Stimulator Implantation,” Neurosurgery, Official Journal of the Congress of Neurological Surgeons, vol. 28, No. 5, May 1991, 9 pages. |
North et al., “Spinal Cord Stimulation for Axial Low Back Pain,” SPINE, vol. 30, No. 12, 2005, 7 pages. |
North et al., “Spinal Cord Stimulation for Chronic, Intractable Pain: Experience over Two Decades,” Neurosurgery, vol. 32, No. 2, Mar. 1993, 12 pages. |
Notice of Allowance for U.S. Appl. No. 13/245,450, First Named Inventor: Konstantinos Alataris, dated Mar. 14, 2012, 8 pages. |
Notice of Opposition to a European Patent for European Patent No. 2586488, Proprietor of the Patent: Nevro Corporation; Opponent: Medtronic, Inc., Mar. 15, 2017, 7 pages. |
Notice of Opposition to a European Patent, Argument and Facts, for European Patent No. 2243510, Proprietor of the Patent: Nevro Corporation, Opponent: Medtronic, Jan. 8, 2015, 22 pages. |
Notice of Opposition to a European Patent, Argument and Facts, and Annex for European Patent No. 2243510, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Jan. 8, 2015, 28 pages. |
Notice of Opposition to a European Patent, Argument and Facts, for European Patent No. 2207587, Proprietor of the Patent: Nevro Corporation; Opponent: Medtronic, Inc., Jan. 12, 2016, 22 pages. |
Notice of Opposition to a European Patent, Argument and Facts, for European Patent No. 2207587, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Jan. 8, 2016, 17 pages. |
Notice of Opposition to a European Patent, Argument and Facts for European Patent No. 2630984, Proprietor of the Patent: Nevro Corporation; Opponent: Medtronic, Mar. 17, 2015, 17 pages. |
Notice of Opposition to a European Patent, Argument and Facts, and Annex for European Patent No. 2630984, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Mar. 17, 2015, 21 pages. |
Notice of Opposition to a European Patent, Argument and Facts, and Annex for European Patent No. 2421600, Proprietor of the Patent: Nevro Corporation; Opponent: Boston Scientific Neuromodulation Corporation, Dec. 4, 2014, 22 pages. |
Oakley et al., “A New Spinal Cord Stimulation System Effectively Relieves Chronic, Intractable Pain: A Multicenter Prospective Clinical Study,” Neuromodulation: Technology at the Neural Interface, vol. 10, No. 3, 2007, 17 pages. |
Oakley et al., “Spinal Cord Stimulation in Axial Low Back Pain: Solving the Dilemma,” Pain Medicine, vol. 7, No. S1, 2006, 6 pages. |
Oakley, John C., “Spinal Cord Stimulation Mechanisms of Action,”SPINE vol. 27, No. 22, copyright 2002, 10 pages. |
Opponent Boston Scientific: Response to Attend Oral Proceedings for European Patent No. 2630984, mailed Oct. 25, 2016, 21 pages. |
Opponent Response to Patent Proprietor Comments to Declaration of Dr. Jonathan Miller for European Patent No. 2630984, mailed Nov. 22, 2016, 3 pages. |
Opponents Boston Scientific Neuromodulation Corp.: Additional Observations in view of Oral Proceedings for European Patent No. 2243510, mailed Feb. 3, 2017, 8 pages. |
Opponents Boston Scientific: Response to Summons to Attend Oral Proceedings for European Patent No. 2421600, mailed Jan. 2, 2017, 15 pages. |
Opponents Medtronic, Inc.: Additional Observations in view of Oral Proceedings for European Patent No. 2243510, mailed Feb. 3, 2017, 10 pages. |
Opponents Medtronic, Inc.: Response to Attend Oral Proceedings for European Patent No. 2630984, mailed Oct. 25, 2016, 26 pages. |
Opponents Response to Patentee's (Nevro) Written Submissions for European Patent No. 2243510, mailed Feb. 22, 2016, 21 pages. |
Palmer et al., “Transcutaneous electrical nerve stimulation and transcutaneous spinal electroanalgesia: A preliminary efficacy and mechanisms-based investigation,” Physiotherapy, 95, 2009, 7 pages. |
Partial European Search Report, European Application No. EP10160641, Applicant: Nevro Corporation, dated Aug. 30, 2010, 3 pages. |
Patent Owner's Preliminary Response for Inter Partes Review for U.S. Pat. No. 8,359,102, Case No. IPR2015-01203, Petitioner: Boston Scientific Neuromodulation Corporation, Patent Owner: Nevro Corporation, dated Sep. 1, 2015, 70 pages. |
Patent Owner's Preliminary Response for Inter Partes Review for U.S. Pat. No. 8,359,102, Case No. IPR2015-01204, Petitioner: Boston Scientific Neuromodulation Corporation, Patent Owner: Nevro Corporation, dated Sep. 1, 2015, 63 pages. |
Perruchoud et al., “Analgesic Efficacy of High-Frequency Spinal Cord Stimulation: A Randomized Double-Blind Placebo-Controlled Study,” Neuromodulation: Technology at Neural Interface, International Neuromodulation Society, 2013, 7 pages. |
Petition for Inter Partes Review of Claims 1, 2, 11-15, 17-23, 25 and 26 for U.S. Pat. No. 8,359,102, Petitioner: Boston Scientific Neuromodulation Corporation, Patent Owner: Nevro Corporation, May 14, 2015, 45 pages. |
Petition for Inter Partes Review of Claims 1, 2, 11-15, 17-23, 25 and 26 for U.S. Pat. No. 8,359,102, Petitioner: Boston Scientific Neuromodulation Corporation, Patent Owner: Nevro Corporation, May 14, 2015, 67 pages. |
Prausnitz et al., “The Effects of Electric Current Applied to Skin: A Review for Transdermal Drug Delivery,” Advanced Drug Delivery Reviews 18, 1996, 31 pages. |
Reddy et al., “Comparison of Conventional and Kilohertz Frequency Epidural Stimulation in Patients Undergoing Trailing for Spinal Cord Stimulation: Clinical Considerations,” World Neurosurgery, www.sciencedirect.com, 6 pages, 2015. |
Remedi Pain Relief—ENM (Electronic Nerve Modulation), https://web.archive.org/web/20050906181041/http://www.remediuk.com/trials.htm, 2005, 5 pages. |
Resume of Jason D. Rahn, Jan. 7, 2015, 2 pages. |
Robb et al., “Transcutaneous Electrical Nerve Stimulation vs. Transcutaneous Spinal Electroanalgesia for Chronic Pain Associated with ; Breast Cancer Treatments,” Journal of Pain and Symptom Management, vol. 33, No. 4, Apr. 2007, 10 pages. |
Royle, John., “Transcutaneous Spinal Electroanalgesia and Chronic Pain,” Physiotherapy, vol. 86, No. 5, May 2000, 1 page. |
Science Daily, “Chronic Pain Costs U.S. up to $635 billion, study shows,” www.sciencedaily.com/releases/2012/09/120911091100.htm, Sep. 11, 2012, 2 pages. |
Senza Spinal Cord Stimulation (SCS) System—P130022, http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm449963.htm Oct. 14, 2016, 2 pages. |
Shealy MD, C. Norman et al., “Electrical Inhibition of Pain by Stimulation of the Dorsal Columns: Preliminary Clinical Report,” Anesthesia and Analgesia Current Researches, vol. 446, No. 4, Jul.-Aug. 1967, 3 pages. |
Simpson et al., “A Randomized, Double-Blind, Crossover Study of the Use of Transcutaneous Spinal Electroanalgesia in Patients with Pain from Chronic Critical Limb Ischemia,” Journal of Pain and Symptom Management, vol. 28, No. 5, Nov. 2004, 6 pages. |
Simpson, BA, “Spinal Cord Stimulation in 60 cases of Intractable Pain.” Journal of Neurology, Neurosurgery and Psychiatry, 1991; 54 pp. 196-199. |
Simpson, BA, “Spinal Cord Stimulation.” British Journal of Neurosurgery, 1997, Feb. 11 (1), 5-11, 7 pages. |
Sluijter et al., “The Effects of Pulsed Radiofrequency Fields Applied to the Dorsal Root Ganglion—A Preliminary Report,” The Pain Clinic, vol. 11, No. 2, 1998, 12 pages. |
Solomonow et al., “Control of Muscle Contractile Force through Indirect High-Frequency Stimulation,” AM Journal of Physical Medicine, 1983, vol. 62, No. 3, pp. 71-82. |
St. Jude Medical, “Eon Mini™ Rechargeable IPG,” Apr. 29, 2013, 3 pages. |
St. Jude Medical, “Individualized Therapy through Diverse Lead Options,” 2008, 6 pages. |
Stimwave, News Release: “Stimwave Receives FDA Approval for High Frequency IDE,” http://stimwave.com/newsroom/latest-news, Jun. 9, 2015, 2 pages. |
Sweet et al., “Paresthesia-Free High Density Spinal Cord Stimulation for Postlaminectomy Syndrome in a Prescreened Population: A Prospective Case Series,” Neuromodulation: Technology at the Neural Interface, 2015, 7 pages. |
Swigris et al., “Implantable Spinal Cord Stimulator to Treat the Ischemic Manifestations of Thromboangiitis Obliterans (Buerger's disease),” Journal of Vascular Surgery, vol. 29, No. 5, 1998, 8 pages. |
Tan et al., “Intensity Modulation: A Novel Approach to Percept Control in Spinal Cord Stimulation,” Neuromodulation Technology at the Neural Interface, International Neuromodulation Society 2015, 6 pages. |
Tanner, J.A., “Reversible blocking of nerve conduction by alternating-current; excitation,” Nature, Aug. 18, 1962; 195: 712-3. |
Tesfaye et al., “Electrical Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy,” The Lancet, vol. 348, Dec. 21-28, 1996, 4 pages. |
Thompson et al., “A double blind randomised controlled clinical trial on the effect of transcutaneous spinal electroanalgesia (TSE) on low back pain,” European Journal of Pain, vol. 12, Issue 3, Apr. 2008, 6 pages. |
Tollison et al., “Practical Pain Management Neurostimulation Techniques,” Chapter 12, Lippincott Williams and Wilkins, Third Edition, 2002, 13 pages. |
Towell et al., “High Frequency non-invasive stimulation over the spine: Effects on mood and mechanical pain tolerance in normal subjects,” Behavioral Neurology, vol. 10, 1997, 6 pages. |
Urban et al., “Percutaneous epidural stimulation of the spinal cord for relief of pain—Long Term Results,” Journal of Neurosurgery, vol. 48, Mar. 1978, 7 pages. |
Van Butyen et al., “High Frequency Spinal Cord Stimulation for the Treatment of Chronic Back Pain Patients: Results of a Prospective Multicenter European Clinical Study,” Neuromodulation Technology at the ; Neural Interface, International Neuromodulation Society, 2012, 8 pages. |
Van Den Honert et al. “Generation of Unidirectionally Propagated Action Potentials Nerve by Brief Stimuli” Science, vol. 26, pp. 1311-1312. |
Van Den Honert, Mortimer JT, “A Technique for Collision Block of Peripheral Nerve: Frequency Dependence,” MP-11 IEEE Trans. Biomed, Eng. 28: 379-382, 1981. |
Van Havenbergh et al., “Spinal Cord Stimulation for the Treatment of Chronic Back Pain Patients: 500-Hz vs. 1000-Hz Burst Stimulation,” Neuromodulation: Technology at the Neural Interface, International Neuromodulation Society, 2014, 4 pages. |
Wallace et al., Poster: “Accelerate: A Prospective Multicenter Trial Evaluating the Use of High-Rate Spinal Cord Stimulation in the Management of Chronic Intractable Pain,” Boston Scientific Corporation, 2015, 1 page. |
Webster's Third New International Dictionary of the English Language Unabridged, “Paresthesia,” 1993, 3 pages. |
Wolter et al., “Continuous Versus Intermittent Spinal Cord Stimulation: An Analysis of Factors Influencing Clinical Efficacy,” Neuromodulation: Technology at Neural Interface, www.neuromodulationjournal.com, 2011, 8 pages. |
Woo MY, Campbell B. “Asynchronous Firing and Block of Peripheral Nerve Conduction by 20KC Alternating Current,” Los Angeles Neuro Society, Jun. 1964; 87-94, 5 pages. |
Zhang et al., “Simulation Analysis of Conduction Block in Myelinated Axons Induced by High-Frequency Biphasic Rectangular Pulses,” IEEE Transactions on Biomedical Engineering, vol. 53., No. 7, Jul. 2006, 4 pages. |
Medtronic—Neurological Division, Resume TL, Model 3986, Lead Kit for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), Implant Manual, 1996, 27 pages. |
Medtronic—Neurostimulation Systems: Expanding the Array of Pain Control Solutions, 1999, 6 pages. |
Kulkarni et al., “A two-layered forward model of tissue for electrical impedance tomography,” Physiol Meas., 30(6); pp. 1-24, Jun. 2009. |
Number | Date | Country | |
---|---|---|---|
20210060338 A1 | Mar 2021 | US |
Number | Date | Country | |
---|---|---|---|
62286892 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15414561 | Jan 2017 | US |
Child | 17030349 | US |